Abstract
Introduction: We aimed to define a Mayo Preclinical Alzheimer's disease Cognitive Composite (Mayo-PACC) that prioritizes parsimony and use of public domain measures to facilitate clinical translation. Methods: Cognitively unimpaired participants aged 65 to 85 at baseline with amyloid PET imaging were included, yielding 428 amyloid negative (A-) and 186 amyloid positive (A+) individuals with 7 years mean follow-up. Sensitivity to amyloid-related cognitive decline was examined using slope estimates derived from linear mixed models (difference in annualized change across A+ and A- groups). We compared differences in rates of change between Mayo-PACC and other composites (A+ > A- indicating more significant decline in A+). Results: All composites showed sensitivity to amyloid-related longitudinal cognitive decline (A+ > A- annualized change p < 0.05). Comparisons revealed that Mayo-PACC (AVLT sum of trials 1-5+6+delay, Trails B, animal fluency) showed comparable longitudinal sensitivity to other composites. Discussion: Mayo-PACC performs similarly to other composites and can be directly translated to the clinic.
Original language | English (US) |
---|---|
Pages (from-to) | 2575-2584 |
Number of pages | 10 |
Journal | Alzheimer's and Dementia |
Volume | 19 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2023 |
Keywords
- ADCS-PACC
- PACC-R
- aging
- amyloid
- biomarker
- cognitive decline
- cognitive outcome measure
- embedded pragmatic clinical trials
- global cognition
- longitudinal
- neuropsychology
- practice effect
- reliability
- validity
ASJC Scopus subject areas
- Epidemiology
- Health Policy
- Developmental Neuroscience
- Clinical Neurology
- Geriatrics and Gerontology
- Cellular and Molecular Neuroscience
- Psychiatry and Mental health